Fulgent Genetics has acquired Fulgent Pharma
This exciting consolidation allows Fulgent to forge a path toward fully integrated precision medicine offerings with an oncology focus.
Current Drug Development &
Drug Delivery Programs
PlatformTargetIndicationDiscoveryPreclinicalPhase 1Phase 2Phase 3
FID - 007
(Small Molecule)
CytotoxicLung, Pancreatic, Head & Neck, Breast Cancer
FID - 007G
(Small Molecule Combo)
CytotoxicPancreatic Cancer
FID - 007C
(Small Molecule Combo)
CytotoxicLung Cancer
Targeted Therapies
Targeted TherapyLeukemia and Other Cancermoffitt logo - fulgent pharma
FID - 010
(Small Molecule)
Immuno - oncologyCancerusc logo - fulgent pharma